Logo

ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV

Share this
ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV

ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV

Shots:

  • Shionogi to receive $27.2M up front- $20.4M upon the achievement of a clinical milestone along with royalties on net sales of S-365598 (HIV integrase inhibitor) & will provide the development costs up to an annual maximum
  • The collaboration will advance ViiV Healthcare's pipeline for HIV treatment. The therapy has the potential for use in ultra long-acting HIV regimens with dosing intervals of ≥3mos.
  • The preliminary data showed that S-365598 has a high genetic barrier and a resistance profile that are distinct from dolutegravir and cabotegravir. Additionally- both companies plan to initiate human studies of S-365598 by 2023

  | Ref: ViiV | Image: Businesswire

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions